Printer Friendly

ACUSON SHOWS NEW, INVESTIGATIONAL DOPPLER TISSUE IMAGING AT ACC, SAYS: 'DETECTS AND ENHANCES DIAGNOSIS OF CARDIAC ABNORMALITIES MORE QUICKLY'

 ANAHEIM, Calif., March 15 /PRNewswire/ -- A new investigational ultrasound technology that detects and displays myocardial wall motion to enhance rapid visualization of abnormal cardiac function was shown today by Acuson Corp. (NYSE: ACN).
 Doppler Tissue Imaging(TM), DTI(TM) (patent pending), may offer cardiologists a new diagnostic tool to facilitate accurate detection of heart wall motion abnormalities. DTI may prove especially useful in stress echocardiography, where cardiac abnormalities must be identified rapidly to establish accurate diagnoses.
 The new Doppler Tissue Imaging technology was shown at the 42nd Annual Scientific Session of the American College of Cardiology in Anaheim. It uses new Doppler processing to color encode myocardial wall motion (heart muscle) and provide cardiologists with information on contractile function of moving cardiac tissue.
 "Doppler Tissue Imaging represents a fundamental departure from previous color Doppler ultrasound technology," said Donald Burch, vice president of engineering for Acuson, who was project manager for Acuson's color Doppler technology development in the mid-1980s. "Color Doppler technology is designed to use the Doppler effect to image moving blood and remove the many Doppler signals from moving cardiac tissue. By contrast, DTI uses proprietary signal processing to do the opposite, by using the Doppler effect to image moving cardiac tissue and remove conventional Doppler signals that derive from the moving blood," Burch added.
 According to clinical investigators, DTI may facilitate the detection of wall motion abnormalities more rapidly, which increases the accuracy of the echocardiogram for detection for coronary artery disease.
 In clinical evaluations, researchers also found that DTI used with dobutamine stress echoes helped to visually enhance myocardial wall motion on particularly difficult-to-image patients, enabling increased confidence of myocardial activity and producing higher quality images more quickly. Dobutamine is a chemical compound used by cardiologists to chemically increase heart rate and contractility.
 Additionally, clinical studies found that DTI is capable of differentiating a normally contracting myocardium from an injured myocardium, enabling more accurate assessment of myocardial viability.
 Acuson, based in Mountain View, Calif., is the leading independent manufacturer of high performance medical diagnostic ultrasound equipment. The company had worldwide sales of $343 million in 1992.
 NOTE: Doppler Tissue Imaging and DTI are trademarks of Acuson Corp.
 -0- 3/15/93
 /CONTACT: Charlie Purdom of Purdom Public Relations, 415-588-5700, for Acuson/
 (ACN)


CO: Acuson Corp. ST: California IN: CPR MTC SU: PDT

SG -- SJ004 -- 5896 03/15/93 09:03 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 15, 1993
Words:394
Previous Article:THE WILLIAMS COMPANIES TO REORGANIZE ITS ENERGY-RELATED BUSINESSES
Next Article:WEATHERFORD INTERNATIONAL ANNOUNCES OFFERING
Topics:


Related Articles
ACUSON'S NEW 'ACOUSTIC RESPONSE TECHNOLOGY' CALLED FUNDAMENTAL TO DIAGNOSTIC ULTRASOUND
NEW ULTRASOUND TECHNOLOGY, PROCEDURES AID HEART DOCTORS, SAVE COSTS, CARDIAC SPECIALISTS TOLD AT S.F. CONFERENCE
NEW ULTRASOUND TECHNOLOGY, PROCEDURES AID HEART DOCTORS, SAVE COSTS, CARDIAC SPECIALISTS TOLD AT S.F. CONFERENCE
ACUSON'S ACOUSTIC RESPONSE TECHNOLOGY GAINS RAPID MARKET ACCEPTANCE, SALES FIGURES SHOW
ACUSON ANNOUNCES NEW QUANTX(TM) COLOR QUANTIFICATION TOOLS FOR ECHOCARDIOGRAPHY AS 'WORKS-IN-PROGRESS'
U.S.-CHINA INDUSTRIAL EXCHANGE, INC. AND ACUSON CORPORATION LAUNCH SEQUOIA ULTRASOUND SCANNER IN BEIJING
Acuson's Sequoia(TM) Platform Drives Emerging Applications With High Frequency Imaging and Superb Detail Resolution
Acuson, Mallinckrodt Form Partnership For Marketing Cardiac Ultrasound Contrast Agent.
World Renowned Cosmonaut and Physician Uses Ultrasound to Study the Effects Of Space Travel on the Human Heart.
Acuson Files for 510(k) Clearance With the FDA for the AcuNav(TM) Diagnostic Ultrasound Catheter That Captures Images From Inside the Heart.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters